Sponsor Pipeline

Kami Maddocks, MD Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
2
Active Trials
0
Recruiting
4
Disease Areas
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-07-23 NCT01479842
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma		 date change Primary completion pushed: 2026-07-01 -> 2026-12-01
2026-07-23 NCT01479842
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma		 date change Completion pushed: 2026-09-01 -> 2026-12-01
Active Trials by Phase
Phase 2
1
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT01589302 PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic… Prolymphocytic Leukemia Active, Not Recruiting
Phase 1
NCT01479842 Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Active, Not Recruiting
Disease Areas
Follicular Lymphoma (1) Mantle Cell Lymphoma (1) Leukemia (1) Chronic Lymphocytic Leukemia (CLL) (1)
Get alerts when Kami Maddocks, MD's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free